Loading company…
Yinuokang develops targeted protein degradation and tumor immune drugs.
Founded in 2021 and based in Nanjing, China, Yinuokang Biomedical develops anticancer drugs focused on targeted protein degradation and tumor immunity. Its activities include drug research and development, pharmaceutical commissioning, and clinical trial services. In December 2023, it raised approximately CNY 100 million in pre-Series A funding led by Golden China Fund.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign inWork at Yinuokang (Nanjing) Biomedical Co., Ltd.? This is my company